This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Antiplatelet drugs for secondary prevention of stroke

Authoring team

Patients with stroke or TIA should receive two weeks of aspirin followed by definitive anti-platelet treatment (1):

  • clopidogrel is recommended as an option to prevent occlusive vascular events:
    • for people who have had an ischaemic stroke or who have peripheral arterial disease or multivascular disease or
    • for people who have had a myocardial infarction only if aspirin is contraindicated or not tolerated

  • modified-release dipyridamole in combination with aspirin is recommended as an option to prevent occlusive vascular events:
    • for people who have had a transient ischaemic attack or
    • for people who have had an ischaemic stroke only if clopidogrel is contraindicated or not tolerated

  • modified-release dipyridamole alone is recommended as an option to prevent occlusive vascular events:
    • for people who have had an ischaemic stroke only if aspirin and clopidogrel are contraindicated or not tolerated or
    • for people who have had a transient ischaemic attack only if aspirin is contraindicated or not tolerated

People currently receiving clopidogrel or modified-release dipyridamole either with or without aspirin outside the criteria detailed above should have the option to continue treatment until they and their clinicians consider it appropriate to stop

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.